April 3rd 2025
Sitting down with the PharmTech Group at INTERPHEX 2025, Nicole Hunter, head of Global WMArchitect at WMFTS, explains the industry initiative around single-use assembly components resulting from supply disruptions caused by the COVID-19 pandemic.
The Shape of Biopharmaceutical Facilities to Come
March 18th 2009The spotlight on the biopharmaceutical industry is intensifying, as recently evidenced by Pfizer's (New York) ongoing acquisition of Wyeth (Madison, NJ), which was initiated partly to reduce the former's dependence on small-molecule drugs.
Manufacturing High-Potency Drugs Using Isolators
November 1st 2008The author discusses the key issues to consider when using isolators such as containment, protection of personnel, the efficiency of biodecontamination cycles, sterility assurance levels, barriers and their integrity, and environmental impact.
Polysaccharide-Based Chiral Chromatography Media in HPLC and SFC
October 1st 2007Polysaccharide-based chiral stationary phases have been developed that comprise chiral selectors immobilized on their support rather than being physically coated. These materials are completely solvent stable, thereby increasing selectivity and and enabling the development of new chiral selectors that have been too unstable in a coated form for general use.
RABS and Advanced Aseptic Processing
May 1st 2006Any aseptic processing technology that allows intervention by gowned personnel during operation cannot be considered an advanced technology. Although a standardized definition of restricted access barrier systems has been developed, these systems fall well short of being classfied as advanced technologies.
The Next Generation of Aseptic Processing Equipment
May 1st 2006The industry has acknowledged only recently the significance of the contamination risk posed by humans. The authors assert that this realization, together with technological advances, will lead to the elimination of human intervention and, hence, improved sterility.